Government

House and Senate Version of FDARA/FDA Amendements Act Compared

 Full Text of Legislation

• H.R.3580, Food and Drug Administration Amendments Act of 2007 (Engrossed as Agreed to or Passed by House)
• S. 1082: FDA Revitalization Act
• H.R. 2900: FDA Amendments Act of 2007

House Energy & Commerce Committee, Health Subcommittee

• Hearings
  • June 12, 2007
  • May 16, 2007
  • April 17, 2007
• Subcommittee Markups
  • June 21, 2007
  • June 19, 2007
• Statements
  • Statement of Senator Edward M. Kennedy on Passage of FDA Bill
  • Statement of Senator Edward M. Kennedy on House Passage of the House Passage of FDA Bill
  • Dingell Introduces H.R. 3610, the "Food and Drug Import Safety Act of 2007"
  • Congressman Frank Pallone, JR. (D-NJ)

Senate Health, Education, Labor and Pensions (HELP) Committee, Health Subcommittee

• Hearings
  • Drug User Fees: Enhancing Patient Access and Drug Safety
  • Hearing on Building a 21st Century FDA: Proposals to Improve Drug Safety and Innovation

Senate Finance Committee 

• Hearing
  • FDA, Merck and Vioxx: Putting Patient Safety First?
• Statements
  • Senator Chuck Grassley Statement on S.1082

Government Accountability Office (GAO)

• Reports
  • Improvement Needed in FDA's Postmarket Decision-making and Oversight Process; Report to Congressional Requesters
  • FOOD AND DRUG ADMINISTRATION: Effect of User Fees on Drug Approval Times, Withdrawals and Other Agency Activities; Report to the Chairman, Committee on Health, Education, Labor and Pensions, US Senate
• Statements
  • Further Actions Needed to Improve FDA's Postmarket Decision-making Process; Testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives
  • FDA Needs to Further Address Shortcomings in its Post-marketing Decision-making Process; Testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives

Upcoming Events

December 4, 2007

Experts to Discuss Drug Safety

A group of experts will discuss the patient perspective and medical implications of the FDA Amendments Act 2007. The event will be at the National Press Club.